Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
François PoumeaudM MorisseauLuc CabelA GonçalvesC RivierO TrédanE VolantJean-Sébastien FrenelS LadoireWilliam JacotM JamelotH Foka TichoueAnne PatsourisLuis TeixeiraF-C BidardD LoiratM BrunetC LevyCaroline BailleuxB CabarrouA DeleuzeL UwerE DelucheT GrelletyC FranchetF FiteniH BischoffR VionM PagliucaB VerretS BécourtT ReverdyA de NonnevilleF DalencPublished in: British journal of cancer (2024)
Clinical benefit of sequentially administered SG and T-DXd is limited for most patients. Nevertheless, a subset of patients might benefit-on the short term-from a second ADC. Additional studies are needed to identify patients who could benefit from two ADCs with similar payloads.